Patents Assigned to Micropharm Limited
-
Publication number: 20230165949Abstract: The present application relates to recombinant Clostridium difficile antigens based on a fusion protein that consists of or comprises a first amino acid sequence and a second amino acid sequence, wherein: a) the first amino acid sequence is provided by an amino acid sequence that has at least 80% sequence identity with an amino acid sequence consisting of residues 1500-1850 of a C. difficile Toxin A sequence or residues 1500-1851 of a C. difficile Toxin B sequence; and b) the second amino acid sequence is provided by an amino acid sequence that has at least 80% sequence identity with an amino acid sequence consisting of a long repeat unit located within amino acid residues 1851-2710 of a C. difficile Toxin A sequence or within amino acid residues 1852-2366 of a C. difficile Toxin B sequence; though with the proviso that the fusion protein is not a polypeptide comprising amino acid residues 543-2710 of a C.Type: ApplicationFiled: August 23, 2022Publication date: June 1, 2023Applicants: Secretary of State for Health and Social Care, MicroPharm LimitedInventors: Clifford Shone, April Roberts, Helen Ahern, Michael Maynard-Smith, John Landon
-
Publication number: 20210369830Abstract: The present application relates to recombinant Clostridium difficile antigens based on a fusion protein that consists of or comprises a first amino acid sequence and a second amino acid sequence, wherein: a) the first amino acid sequence is provided by an amino acid sequence that has at least 80% sequence identity with an amino acid sequence consisting of residues 1500-1850 of a C. difficile Toxin A sequence or residues 1500-1851 of a C. difficile Toxin B sequence; and b) the second amino acid sequence is provided by an amino acid sequence that has at least 80% sequence identity with an amino acid sequence consisting of a long repeat unit located within amino acid residues 1851-2710 of a C. difficile Toxin A sequence or within amino acid residues 1852-2366 of a C. difficile Toxin B sequence; though with the proviso that the fusion protein is not a polypeptide comprising amino acid residues 543-2710 of a C.Type: ApplicationFiled: April 7, 2021Publication date: December 2, 2021Applicants: Secretary of State for Health and Social Care, MicroPharm LimitedInventors: Clifford Shone, April Roberts, Helen Ahern, Michael Maynard-Smith, John Landon
-
Publication number: 20210347876Abstract: The present invention is directed to an antibody composition for oral administration comprising intact blood-derived polyclonal antibodies that bind to a human tumour necrosis factor ? (TNF?), and means for protecting the antibodies during gastrointestinal transit, as well as methods for manufacturing, kits, and therapeutic uses of the same.Type: ApplicationFiled: July 19, 2021Publication date: November 11, 2021Applicant: MICROPHARM LIMITEDInventors: John Landon, Ruth Elizabeth Coxon
-
Patent number: 11098114Abstract: The present invention is directed to an antibody composition for oral administration comprising intact blood-derived polyclonal antibodies that bind to a human tumour necrosis factor ? (TNF?), and means for protecting the antibodies during gastrointestinal transit, as well as methods for manufacturing, kits, and therapeutic uses of the same.Type: GrantFiled: January 29, 2018Date of Patent: August 24, 2021Assignee: MICROPHARM LIMITEDInventors: John Landon, Ruth Elizabeth Coxon
-
Patent number: 10519219Abstract: The present invention provides antibodies, for use in the treatment, suppression prevention of Filovirus disease, particularly Ebola virus disease. Also provided immunogens for use in eliciting such antibodies.Type: GrantFiled: February 10, 2016Date of Patent: December 31, 2019Assignees: The Secretary of State for Health, MicroPharm Limited, The Chancellor, Masters and Scholars of the University of OxfordInventors: Miles Carroll, Stuart Dowall, Roger Hewson, Ian Cameron, John Landon, Antra Zeltina, David Stuart, Thomas Bowden
-
Publication number: 20190328859Abstract: The present application relates to recombinant Clostridium difficile antigens based on a fusion protein that consists of or comprises a first amino acid sequence and a second amino acid sequence, wherein: a) the first amino acid sequence is provided by an amino acid sequence that has at least 80% sequence identity with an amino acid sequence consisting of residues 1500-1850 of a C. difficile Toxin A sequence or residues 1500-1851 of a C. difficile Toxin B sequence; and b) the second amino acid sequence is provided by an amino acid sequence that has at least 80% sequence identity with an amino acid sequence consisting of a long repeat unit located within amino acid residues 1851-2710 of a C. difficile Toxin A sequence or within amino acid residues 1852-2366 of a C. difficile Toxin B sequence; though with the proviso that the fusion protein is not a polypeptide comprising amino acid residues 543-2710 of a C.Type: ApplicationFiled: July 15, 2019Publication date: October 31, 2019Applicants: The Secretary of State for Health, MicroPharm LimitedInventors: Clifford Shone, April Roberts, Helen Ahern, Michael Maynard-Smith, John Landon
-
Patent number: 10369206Abstract: The present invention relates to recombinant Clostridium difficile antigens based on a fusion protein that consists of or comprises a first amino acid sequence and a second amino acid sequence, wherein: a) the first amino acid sequence is provided by an amino acid sequence that has at least 80% sequence identity with an amino acid sequence consisting of residues 500-1850 of a C. difficile Toxin A sequence or residues 1500-1851 of a C. difficile Toxin B sequence; and b) the second amino acid sequence is provided by an amino acid sequence that has at least 80% sequence identity with an amino acid sequence consisting of a long repeat unit located within amino acid residues 1851-2710 of a C. difficile Toxin A sequence or within amino acid residues 1852-2366 of a C. difficile Toxin B sequence; though with the proviso that the fusion protein is not a polypeptide comprising amino acid residues 543-2710 of a C.Type: GrantFiled: October 5, 2011Date of Patent: August 6, 2019Assignees: THE SECRETARY OF STATE FOR HEALTH, MICROPHARM LIMITEDInventors: Clifford Shone, April Roberts, Helen Ahern, Michael Maynard-Smith, John Landon
-
Publication number: 20180105580Abstract: The present invention provides antibodies, for use in the treatment, suppression prevention of Filovirus disease, particularly Ebola virus disease. Also provided immunogens for use in eliciting such antibodies.Type: ApplicationFiled: February 10, 2016Publication date: April 19, 2018Applicants: The Secretary of State for Health, MicroPharm Limited, The Chancellor, Masters and Scholars of the University of OxfordInventors: Miles Carroll, Stuart Dowall, Roger Hewson, Ian Cameron, John Landon, Antra Zeltina, David Stuart, Thomas Bowden
-
Publication number: 20150010580Abstract: The present invention provides an antibody composition comprising ovine antibodies, for use in the prevention or treatment of C. difficile infection wherein the antibodies bind to a C. difficile toxin.Type: ApplicationFiled: March 18, 2014Publication date: January 8, 2015Applicants: Micropharm Limited, Health Protection AgencyInventors: Clifford Charles Shone, John Landon
-
Patent number: 8709428Abstract: The present invention provides an antibody composition comprising ovine antibodies, for use in the prevention or treatment of C. difficile infection wherein the antibodies bind to a C. difficile toxin.Type: GrantFiled: February 19, 2010Date of Patent: April 29, 2014Assignees: Health Protection Agency, Micropharm LimitedInventors: Clifford Shone, John Landon
-
Publication number: 20130266583Abstract: The present invention relates to recombinant Clostridium difficile antigens based on a fusion protein that consists of or comprises a first amino acid sequence and a second amino acid sequence, wherein: a) the first amino acid sequence is provided by an amino acid sequence that has at least 80% sequence identity with an amino acid sequence consisting of residues 500-1850 of a C. difficile Toxin A sequence or residues 1500-1851 of a C. difficile Toxin B sequence; and b) the second amino acid sequence is provided by an amino acid sequence that has at least 80% sequence identity with an amino acid sequence consisting of a long repeat unit located within amino acid residues 1851-2710 of a C. difficile Toxin A sequence or within amino acid residues 1852-2366 of a C. difficile Toxin B sequence; though with the proviso that the fusion protein is not a polypeptide comprising amino acid residues 543-2710 of a C.Type: ApplicationFiled: October 5, 2011Publication date: October 10, 2013Applicants: MICROPHARM LIMITED, HEALTH PROTECTION AGENCYInventors: Clifford Shone, April Roberts, Helen Ahern, Michael Maynard-Smith, John Landon
-
Publication number: 20120121607Abstract: The present invention provides an antibody composition comprising ovine antibodies, for use in the prevention or treatment of C. difficile infection wherein the antibodies bind to a C. difficile toxin.Type: ApplicationFiled: February 19, 2010Publication date: May 17, 2012Applicants: Micropharm Limited, Health Protection AgencyInventors: Clifford Shone, John Landon